参考文献/References:
[1] Tanai E,Frantz SPathophysiology of Heart Failure[J]. Compr Physiol,2015,6(1):187-214.
[2] Volpe M,Carnovali M,Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure:from molecular basis to treatment[J]. Clin Sci,2016,130(2):57-77.
[3] Ogawa T,de Bold AJ. The heart as an endocrine organ[J]. Endocr Connect,2014,3(2):R31-R44.
[4] Potter LR. Natriuretic peptide metabolism,clearance and degradation[J]. Febs J,2011,278(11):1808-1817.
[5] Verboven K,Hansen D,Jocken JWE,et al. Natriuretic peptides in the control of lipid metabolism and insulin sensitivity[J]. Obes Rev,2017,18(11):1243-1259.
[6] Liang F,O’Rea J,Schellenberger U,et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide[J]. J Am Coll Cardiol,2007,49(10):1071-1078.
[7] Singh G,Kuc RE,Maguire JJ,et al. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart:downregulation of natriuretic peptide receptor-A in heart failure[J]. Circ Res,2006,99(2):183-190.
[8] Bryan PM,Potter LR. The atrial natriuretic peptide receptor(NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases[J]. J Biol Chem,2002,277(18):16041-16047.
[9] Gopi V,Subramanian V,Manivasagam S,et al. AngiotensinⅡdown-regulates natriuretic peptide receptor-A expression and guanylyl cyclase activity in H9c2 (2-1) cardiac myoblast cells:Role of ROS and NF-kappaB[J]. Mol Cell Biochem,2015,409(1-2):67-79.
[10] Andreassi MG,Del Ry S,Palmieri C,et al. Up-regulation of “clearance” receptors in patients with chronic heart failure:a possible explanation for the resistance to biological effects of cardiac natriuretic hormones[J]. Eur J Heart Fail,2001,3(4):407-414.
[11] Knecht M,Pagel I,Langenickel T,et al,Increased expression of renal neutral endopeptidase in severe heart failure[J].Life Sci,2002,71(23):2701-2712.
[12] Yanaka N,Kurosawa Y,Minami K,et al. cGMP-phosphodiesterase activity is up-regulated in response to pressure overload of rat ventricles[J]. Biosci Biotechnol Biochem,2003,67(5):973-979.
[13] Menon SG,Mills RM,Schellenberger U,et al. Clinical implications of defective B-type natriuretic peptide[J].Clin Cardiol,2009,32(12):E36-E41.
[14] Okolicany J,McEnroe GA,Koh GY,et al. Clearance receptor and neutral endopeptidase-mediated metabolism of atrial natriuretic factor[J]. J Am Coll Cardiol,1992,263(3):F546-F553.
[15] Chen Y,Burnett JC. Biochemistry,therapeutics,and biomarker implications of neprilysin in cardiorenal disease[J]. Clin Chem,2017,63(1):108-115.
[16] Maguer-Satta V,Besancon R,Bachelard-Cascales E. Concise review:neutral endopeptidase (CD10):a multifaceted environment actor in stem cells,physiological mechanisms,and cancer[J]. Stem Cells,2011,29(3):389-396.
[17] Packer M,Califf RM,Konstam MA,et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure[J]. Circulation,2002,106(8):920-926.
[18] Zanchi A,Maillard M,Burnier M. Recent clinical trials with omapatrilat:new developments[J]. Curr Hypertens Rep,2003,5(4):346-352.
[19] McMurray JJV,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004.
[20] 刘滔,徐俊波,吴镜. 沙库巴曲缬沙坦治疗心力衰竭的新进展[J]. 心血管病学进展,2018,39(3):483-486.
[21] Tsutsui H,Momomura S,Saito Y,et alEfficacy and safety of sacubitril/valsartan(LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction:Rationale for and design of the randomized,double-blind PARALLEL-HF study[J]. J Cardiol,2017,70(3):225-231.
[22] Velazquez EJ,Morrow DA,DeVore AD,et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med,2019,380(6):539-548.
[23] Pascual-Figal D,Wachter R,Senni M,et al. Rationale and design of TRANSITION:a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan[J]. ESC Heart Fail,2018,5(2):327-336.
[24] Solomon SD,Rizkala AR,Gong J,et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction:rationale and design of the PARAGON-HF trial[J]. JACC Heart Fail,2017,5(7):471-482.
[25] Sarrias A,Bayes-Genis A. Is sacubitril/valsartan (also) an antiarrhythmic drug?[J]. Circulation,2018,138(6):551-553.
[26] Seferovic JP,Claggett B,Seidelmann SB,et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes:a post-hoc analysis from the PARADIGM-HF trial[J]. Lancet Diabetes Endocrinol,2017,5(5):333-340.
[27] Damman K,Gori M,Claggett B,et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure[J]. JACC Heart Fail,2018,6(6):489-498.
[28] Haynes R,Judge PK,Staplin N,et al. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease[J]. Circulation,2018,138(15):1505-1514.
[29] Januzzi JL,Prescott MF,Butler J,et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction[J]. JAMA,2019,322(11):1085.
[30] Wachter R,Viriato D,Klebs S,et al. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany[J]. Postgrad Med,2018,130(3):308-316.
[31] Canu A,Hebert M,Gachet A,et al. Results of a single center experience on 110 consecutive patients treated with Entresto(sacubitril/valsartan)[J]. Arch Cardiovasc Dis Supplements,2017,9(1):33.
[32] Haddad H,Bergeron S,Ignaszewski A,et al. The PARASAIL study-patient reported outcomes from the Canadian real world experience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction[J]. J Card Fail,2018,24(8):S55-S56.
[33] Chang HY,Feng AN,Fong MC,et al. Sacubitril/valsartan in heart failure with reduced ejection fraction patients:Real world experience on advanced chronic kidney disease,hypotension,and dose escalation[J]. J Cardiol,2019,74(4):372-380.
[34] Seferovic PM,Ponikowski P,Anker SD,et al. Clinical practice update on heart failure 2019:pharmacotherapy,procedures,devices and patient management.An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail,2019,21(10):1169-1186.
[35] Chang HY,Chen KC,Fong MC,et al. Recovery of left ventricular dysfunction after sacubitril/valsartan:predictors and management[J]. J Cardiol,2019,3(75): P233-P241.
[36] Krittanawong C,Kitai T,Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects[J].Cardiovasc Ther,2017,35(4):e12272.
[37] Langenickel TH,Tsubouchi C,Ayalasomayajula S,et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid-beta concentrations in cerebrospinal fluid in healthy subjects[J]. Br J Clin Pharmacol,2016,81(5):878-890.
[38] Shipp MA,Tarr GE,Chen CY,et al. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung[J]. P Natl Acad Sci Usa,1991,88(23):10662-10666.
[39] Kuniyasu H,Luo Y,Fujii K,et al. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver[J]. Gut,2010,59(3):348-356.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(4):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(4):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(4):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(4):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(4):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]